Leukemia Research

Article	Citations
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase	74
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia	41
A concise review on the molecular genetics of acute myeloid leukemia	36
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆	35
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study	28
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia	26
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival	21
Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment	21
Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism	21
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis	20
Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment	20
Clonal hematopoiesis: Molecular and clinical implications	19
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm	18
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia	18
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells	18
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies	17
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study	17
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia	17
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement	16
Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia	16
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation	15
The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis	14
Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?	14
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience	14
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias	13

miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia	12
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)	12
A machine learning approach to predicting risk of myelodysplastic syndrome	12
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis	11
Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma	11
Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis	11
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious	11
Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients	11
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions	10
Association of insurance disparities and survival in adults with multiple myeloma: A non-concurrent cohort study	10
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes	10
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia	10
Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes	10
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma	9
Sweet's syndrome associated with hematological malignancies	9
High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era	9
Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantatio	9
NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma	9
Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia	9
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience	9
MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)	8
A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors	8
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma	8
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS	8
LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia	8
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy	8
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1	8
Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study	8
MYC overexpression is associated with an early disease progression from MDS to AML	8
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation	8
IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia	8
High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia	8
Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles	8
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights	8
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy	7
Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report	7
Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia	7
Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications	7
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy	7
Integration of the Ki-67 proliferation index into the Ogata score improves its diagnostic sensitivity for low-grade myelodysplastic syndromes	7
Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia	7
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma	7
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues	7
Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells	7
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax	7
Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review	7
Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia	7
Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase	7
The incidence of non-Hodgkin lymphoma is increased in patients with obstructive sleep apnea	6
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib	6

MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner	6
No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)	6
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic l	6
Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort	6
Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia	6
Diminished expression of 5hmc in Reed-Sternberg cells in classical Hodgkin lymphoma is a common epigenetic marker	6
Incidence of myelodysplastic syndromes in Finland 1997–2016	6
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma	6
Antihistamines are synergistic with Bruton’s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells	6
Efficacy of 10-day decitabine in acute myeloid leukemia	6
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)	6
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia	6
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients	6
The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era	6
Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study	6
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry	6
25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma	6
Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study	6
An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells	6
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma	6
MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial	6
Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update	6
From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers	6
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs	6
Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia	6
Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials	6
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system	5
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts	5
MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia	5
Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival	5
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy	5
Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma	5
TH1 cytokines induce senescence in AML	5
Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment	5
Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML	5
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease)	5
Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form?	5
Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice	5
MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12	5
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia	5
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement	5
MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era	5
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial	5
The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T	5
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia	5
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarM	5
Targeted therapy for treatment of patients with classical hairy cell leukemia	5
Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line	5
Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia	5
Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia	5
Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma	5
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008	5
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity	5
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008	5
Evidence that knock down of GSK-3β in Chronic Myelogenous Leukemia cells augments IFN-γ-induced apoptosis	5
The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid	4
Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia	4
Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval	4
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study	4
Treatment of lymphomas via regulating the Signal transduction pathways by natural therapeutic approaches: A review	4
Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous syste	4
CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes	4
De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features	4
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia	4
A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia	4
Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap	4
Central nervous system involvement in adult acute myeloid leukemia patients	4
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort	4
Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis	4
Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT	4
Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre	4
Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome	4
Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis	4
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database	4
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents	4
Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia	4
Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis	4
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center	4
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center	4
High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies	4

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML	4
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells	4
t(3;14)(p14.1;q32)/FOXP1-IGH translocation in thyroid extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)	4
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting	4
The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009	4
Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy	4
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines	4
Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population	4
Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease	4
Low serum cholesterol levels predict inferior prognosis and improve prognostic index scoring for peripheral T-cell lymphoma, unspecified	4
Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia	4
Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study	4
Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay	4
Plasmablastic lymphoma – single centre experience with infusional EPOCH chemotherapy	4
Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system	4
The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?	4
Evidence that PKCα inhibition in Dalton’s Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis	4
Effects of neuromuscular electrical stimulation combined with resistance exercises on muscle strength in adult hematological cancer patients: A randomized controlled study	3
What’s germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening	3
Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients	3
Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia	3
Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma	3
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI	3
Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia	3
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography	3
Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL	3
A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia	3
Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities	3
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA	3
Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma	3
Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy	3
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial	3
Clonal hematopoiesis: Molecular basis and clinical relevance	3
Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia	3
Chronic lymphocytic leukemia in a young population	3
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group	3
Anabolic steroids in myelodysplastic syndromes: A systematic review	3
Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak	3
CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations	3
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial	3
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms	3
Autoimmune disorders and the risk of thrombotic events in polycythaemia vera	3
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients	3
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis	3
Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen	3
Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR	3
Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions	3
A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia	3
Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis	3
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia	3
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta	3
Clonal Hematopoiesis: Origins and determinants of evolution	3
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest	3
Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database	3
Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England	3
Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma	3
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis	3
Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma	3
CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/β-catenin pathway	3
Strategy for identification of a potential inherited leukemia predisposition in a 299 patient’s cohort with tumor-only sequencing data	3
Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes	3
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future	3
Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort	3
Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia	3
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms	3
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry	3
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia	3
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study	2
Acquired alpha thalassemia associated with myeloid malignancy: A systematic literature review	2
Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia	2
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis	2
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events	2
Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives	2
The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia	2
Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab	2
Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia – Another manifestation of a stem cell neoplasm	2
Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic neoplasm	2
Prognostic impact of red cell distribution width in adult T-cell leukemia/lymphoma	2
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group	2
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy	2
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data	2
MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia	2
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis	2
The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study	2
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution	2
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies	2
PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation	2
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes	2
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis	2
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study	2
A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis	2
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN	2
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis	2
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas	2
Diagnostic performance of F-18 FDG PET/CT in the detection of bone marrow involvement in paediatric hodgkin lymphoma: A meta-analysis	2